"We are pleased to continue our partnership with Caris to support their advancement of molecular profiling,", OrbiMed Partner, said in the release."Caris has shown the value of a comprehensive approach, and we are excited by the potential of Caris' proprietary dataset and technology."
Founded in 2008, Caris Life Sciences is a molecular science and technology company that has created a database to analyze the complexity of the disease. The database also analyzes patients' DNA, RNA and protein biomarkers to select the most appropriate therapies. According to the release, the company has a molecular database of over 455,000 tumor profiles and over 350,000 profiles with matched data and clinical outcomes.
لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر: